
|Articles|April 15, 2003
Antibiotic combats acute bacterial conjunctivitis
Andover, MA-The antibiotic ISV-401 (InSite Vision, Alameda, CA) in development to treat acute bacterial conjunctivitis has achieved a bacterial eradication rate of 85% by the third day of treatment and 90% by 7 to 9 days, according to a phase II clinical trial.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Q&A: William F. Wiley, MD, on what BVI's trifocal IOL approval means for US premium vision options
2
What if? Ophthalmology without OCT – Part 1
3
ICYMI: AAO 2025 showcases new technologies and continued research
4
AAO 2025: Ophthalmic World Leaders honors 2025 leadership awardees
5

















































.png)


